Figure 8. Dual bortezomib and K145 therapy has favourable effects on myeloma bone disease.

A. Representative micro CT scans of right-sided iliac crests from female mice in each treatment group. External bone surface (left) is shown to visualise lytic lesions whilst the interior of the bone (right) enables assessment of trabecular integrity. B. Quantitation of total bone volume between groups. C. Quantitation of trabecular volume between treatment groups. Mice receiving the combination of bortezomib and K145 had an average total trabecular volume of 0.37±0.08 mm³ versus 0.23±0.04 mm³ in vehicle-treated animals (P = 0.003) and 0.28±0.08 mm³ in K145-treated animals (P = 0.045). However, there was only a trend towards greater trabecular volume compared to bortezomib treated mice, 0.37±0.08 mm³ versus 0.31±0.09 mm³ in bortezomib-treated animals (P = 0.478). Six female mice were analysed per group with mean±SD shown.